FI118001B - Kerran päivässä suun kautta otettava metoprololiannosmuoto - Google Patents

Kerran päivässä suun kautta otettava metoprololiannosmuoto Download PDF

Info

Publication number
FI118001B
FI118001B FI956210A FI956210A FI118001B FI 118001 B FI118001 B FI 118001B FI 956210 A FI956210 A FI 956210A FI 956210 A FI956210 A FI 956210A FI 118001 B FI118001 B FI 118001B
Authority
FI
Finland
Prior art keywords
metoprolol
tablet
rubber
slow
heteropolysaccharide
Prior art date
Application number
FI956210A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI956210A (fi
FI956210A0 (fi
Inventor
Anand R Baichwal
Troy W Mccall
Original Assignee
Penwest Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceuticals Co filed Critical Penwest Pharmaceuticals Co
Publication of FI956210A publication Critical patent/FI956210A/fi
Publication of FI956210A0 publication Critical patent/FI956210A0/fi
Application granted granted Critical
Publication of FI118001B publication Critical patent/FI118001B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
FI956210A 1994-04-25 1995-12-22 Kerran päivässä suun kautta otettava metoprololiannosmuoto FI118001B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23271994 1994-04-25
US08/232,719 US5399362A (en) 1994-04-25 1994-04-25 Once-a-day metoprolol oral dosage form
US9504118 1995-04-06
PCT/US1995/004118 WO1995028917A1 (en) 1994-04-25 1995-04-06 Once-a-day metoprolol oral dosage form

Publications (3)

Publication Number Publication Date
FI956210A FI956210A (fi) 1995-12-22
FI956210A0 FI956210A0 (fi) 1995-12-22
FI118001B true FI118001B (fi) 2007-05-31

Family

ID=22874261

Family Applications (1)

Application Number Title Priority Date Filing Date
FI956210A FI118001B (fi) 1994-04-25 1995-12-22 Kerran päivässä suun kautta otettava metoprololiannosmuoto

Country Status (16)

Country Link
US (1) US5399362A (de)
EP (3) EP1110542B1 (de)
JP (1) JPH08512062A (de)
KR (1) KR0184339B1 (de)
CN (1) CN1131028C (de)
AT (2) ATE275395T1 (de)
AU (1) AU684944B2 (de)
CA (1) CA2164619C (de)
DE (2) DE69533492T2 (de)
DK (2) DK1110542T3 (de)
ES (2) ES2161882T3 (de)
FI (1) FI118001B (de)
HU (1) HU226375B1 (de)
IL (1) IL113325A (de)
PT (2) PT723435E (de)
WO (1) WO1995028917A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219818B (hu) * 1994-04-25 2001-08-28 Edward Mendell Co. Inc. Elnyújtott hatóanyag-leadású hordozóanyag
WO1997026865A1 (en) * 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Sustained release excipient
WO2001022940A1 (en) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
CA2440641A1 (en) * 2001-03-13 2002-09-19 Anand R. Baichwal Chronotherapeutic dosage forms containing glucocorticosteroid
CA2452871C (en) 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
JP2005022975A (ja) * 2001-08-09 2005-01-27 Wakunaga Pharmaceut Co Ltd 徐放性医薬組成物
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
AU2003230805A1 (en) * 2002-04-05 2003-10-27 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
US6936574B2 (en) * 2002-08-30 2005-08-30 Halliburton Energy Services, Inc. Process for controlling gas migration during well cementing
SI1685829T1 (sl) 2002-11-22 2008-08-31 Gruenenthal Gmbh Uporaba (1RS,3RS,6RS)-6-dimetilaminometil-1- (3-metoksi-fenil)-cikloheksan-1, 3-diola za zdravljenje vnetne bolečine
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
AU2004273958A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
AP2006003585A0 (en) * 2003-09-19 2006-04-30 Penwest Pharmaceuticals Co Delayed release dosage forms.
WO2005077331A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
CA2548864C (en) * 2005-06-06 2012-12-11 Nitto Denko Corporation Percutaneous absorption-type pharmaceutical preparation
EP1743638A1 (de) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmazeutische Formulierungen von substituierten Pyrazolinderivaten
US20070053983A1 (en) * 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
US20110207718A1 (en) 2008-08-06 2011-08-25 Gosforth Centre (Holdings) Pty Ltd. Compositions and methods for treating psychiatric disorders
KR101730924B1 (ko) 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
CN101716157B (zh) * 2008-10-09 2013-02-27 北京德众万全药物技术开发有限公司 一种美托洛尔口服药物组合物及其制备方法
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
WO2011023392A1 (en) 2009-08-28 2011-03-03 Grünenthal GmbH Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an antiepileptic
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
AR081931A1 (es) 2010-06-15 2012-10-31 Gruenenthal Gmbh Combinacion farmaceutica
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
CN102552196B (zh) * 2011-12-20 2013-08-14 中国药科大学 利用喷雾干燥法制备琥珀酸美托洛尔缓释微囊的方法
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
WO2017004526A1 (en) 2015-07-02 2017-01-05 University Of Louisville Research Foundation, Inc. EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303691A (en) * 1977-11-09 1981-12-01 Anderson, Clayton & Co. Proteinaceous food product
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
DE3714074A1 (de) * 1987-04-28 1988-11-10 Hoechst Ag Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US4857331A (en) * 1988-03-31 1989-08-15 Warner-Lambert Company Sugarless pectin delivery system
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol

Also Published As

Publication number Publication date
WO1995028917A1 (en) 1995-11-02
EP0723435A4 (de) 1996-11-06
EP1110542A3 (de) 2001-09-19
ES2161882T3 (es) 2001-12-16
EP0723435B1 (de) 2001-10-24
ATE275395T1 (de) 2004-09-15
FI956210A (fi) 1995-12-22
ES2223669T3 (es) 2005-03-01
EP1470816A3 (de) 2005-03-02
EP1470816A2 (de) 2004-10-27
MX9600024A (es) 1998-11-30
IL113325A (en) 1999-03-12
DK1110542T3 (da) 2005-01-10
US5399362A (en) 1995-03-21
HU9503457D0 (en) 1996-02-28
FI956210A0 (fi) 1995-12-22
DE69523438T2 (de) 2002-05-16
DE69523438D1 (de) 2001-11-29
DK0723435T3 (da) 2002-02-11
HUT75103A (en) 1997-04-28
CN1131028C (zh) 2003-12-17
CA2164619A1 (en) 1995-11-02
DE69533492D1 (de) 2004-10-14
DE69533492T2 (de) 2005-01-27
HU226375B1 (en) 2008-10-28
AU684944B2 (en) 1998-01-08
EP1110542B1 (de) 2004-09-08
KR0184339B1 (ko) 1999-05-01
EP1110542A2 (de) 2001-06-27
EP0723435A1 (de) 1996-07-31
PT1110542E (pt) 2005-01-31
ATE207345T1 (de) 2001-11-15
CN1127470A (zh) 1996-07-24
PT723435E (pt) 2002-02-28
AU2355695A (en) 1995-11-16
IL113325A0 (en) 1995-07-31
CA2164619C (en) 2000-06-20
JPH08512062A (ja) 1996-12-17

Similar Documents

Publication Publication Date Title
FI118001B (fi) Kerran päivässä suun kautta otettava metoprololiannosmuoto
US5399358A (en) Sustained release formulations for 24 hour release of metroprolol
KR100321489B1 (ko) 고용량의불용성약물용서방성매트릭스
FI113337B (fi) Menetelmä pitkitetysti vapauttavan oksibutyniiniä sisältävän valmisteen valmistamiseksi
AU739114B2 (en) Sustained release heterodisperse hydrogel systems - amorphous drugs
US5667801A (en) Sustained release heterodisperse hydrogel systems for insoluble drugs
WO2006094083A1 (en) Controlled release venlafaxine formulations
US20060105035A1 (en) Sustained release heterodisperse hydrogel systems for insoluble drugs
FI119353B (fi) Hitaasti vapauttava täyteaine
MXPA96000024A (en) Form of oral dosing of metoprolol one time
MXPA94008792A (en) Sustained release formulations for 24 hours of metopro release

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118001

Country of ref document: FI

MA Patent expired